Current treatment of lupus nephritis

Lupus

Volumn 17, Issue 5 SPEC. ISS., 2008, Pages 426-430

  Houssiau, F A ^a   Ginzler, E M ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; ANGIOTENSIN RECEPTOR ANTAGONIST; ATACICEPT; AZATHIOPRINE; BELIMUMAB; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPRATUZUMAB; GLUCOCORTICOID; LEUPRORELIN; LOOP DIURETIC AGENT; MESNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PLACEBO; RITUXIMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NAUSEA; NECROTIZING ARTERITIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; TERATOGENICITY;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HUMANS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID;

EID: 44849112235     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308090029     Document Type: Review

References (27)

1. Houssiau, FA. Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15: 2694-2704.
2. Houssiau, FA, Vasconcelos, C, D'Cruz, D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the EuroLupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-3940.
3. Cervera, R, Khamashta, MA, Font, J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299-308.
4. Ginzler, EM, Dooley, MA, Aranow, C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
5. Ginzler, EM, Appel, GB, Dooley, MA, et al. Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): efficacy by racial group. American College of Rheumatology Meeting 2007; Boston, Late Breaking Abstract 13.
6. Moroni, G, Gallelli, B, Ouaglini, S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006; 21: 1541-1548.
7. Blumenfeld, Z, Shapiro, D, Shteinberg, M, Avivi, I, Nahir, M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000; 9: 401-405.
8. Austin, HA, Klippel, JH, Balow, JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
9. Boumpas, DT, Austin, HA, Vaughn, EM, et al. Controlled trial of pusle methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
10. Gourley, MF, Austin, HA, Scott, D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557.
11. Flanc, RS, Roberts, MA, Strippoli, GF, Chadban, SJ, Kerr, PG, Atkins, RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208.
12. Dooley, MA, Hogan, S, Jennette, C, Falk, R. for the Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 1188-1195.
13. Houssiau, FA, D'Cruz, DP, Haga, HJ, Hughes, GR. Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1991; 1: 31-35.
14. Haga, HJ, D'Cruz, D, Asherson, R, Hughes, GR. Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 1992; 51: 885-888.
15. Houssiau, FA, Vasconcelos, C, D'Cruz, D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
16. Cameron, JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424.
17. Urowitz, MB, Ibañez, D, Ali, Y, Gladman, DD. Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide. J Rheumatol 2007; 34: 1491-1496.
18. Grootscholten, C, Ligtenberg, G, Hagen, EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006; 70: 732-742.
19. Grootscholten, C, Bajema, IM, Florquin, S, et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007; 56: 924-937.
20. Chan, TM, Li, FK, Tang, CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
21. Chan, TM, Tse, KC, Tang, CS, Mok, MY, Li, FK. ; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
22. Contreras, G, Pardo, V, Leclercq, B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
23. El Hachmi, M, Jadoul, M, Lefèbvre, C, Depresseux, G, Houssiau, FA. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003; 12: 692-696.
24. Le Meur, Y, Büchler, M, Thierry, A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496-2503.
25. Furie, R. Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. Rheum Dis Clin North Am 2006; 32: 149-156.
26. Wallace, DJ, Lisse, J, Stohl, W, et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks. American College of Rheumatology Meeting 2006; Washington DC, Abstract 2012.
27. Sfikakis, PP, Boletis, JN, Tsokos, GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17: 550-557.